Nestlé, BASF, and Others Move Beyond Fermentation for Affordable HMOs in Infant Formula
Replicating the benefits of human milk oligosaccharides (HMOs) in infant formula is costly and has limited scalability. Traditional fermentation struggles with high expenses. Safety concerns over synthetic alternatives further complicate the development of practical solutions. Advancements in HMO production are beginning to address these roadblocks. For instance, Genechem Inc.’s new method for producing 3-fucosyllactose (3-FL) […]